A newly discovered immune checkpoint could transform how doctors treat autoimmune diseases like lupus by selectively calming overactive B cells rather than wiping out the entire immune system. Scientists have identified a liver-derived protein called fibrinogen-like protein 1 (FGL1) that acts as a natural brake on antibody-producing cells, opening the door to more targeted therapies.

What Is This New Immune Checkpoint, and Why Does It Matter?

Researchers discovered that FGL1 binds to a receptor on B cells called TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor), which is part of the tumor necrosis factor receptor family. This binding suppresses immune responses by pulling the TACI receptor off the B cell surface, reducing the cell's ability to receive activation signals. Think of it like dimming a light switch rather than turning it off completely.

The finding is significant because current lupus treatments often rely on broad immunosuppression or complete B cell depletion, approaches that leave patients vulnerable to infections. The FGL1-TACI pathway offers an alternative by selectively dampening a subset of innate-like B cells without shutting down the entire immune response.

How Did Researchers Make This Discovery?

Scientists already knew that FGL1 worked on T cells as an inhibitory ligand for another receptor called LAG3. However, mice lacking FGL1 developed autoimmune features that differed from mice lacking LAG3, suggesting FGL1 had additional immune-regulatory roles beyond T cells. To investigate, researchers administered recombinant FGL1 to B6/lpr mice, a well-established model of lupus-like autoimmune disease.

The results were striking. Treatment significantly reduced autoimmune manifestations, accompanied by fewer B cells and diminished antigen-specific IgM antibody responses. Using a genome-wide screen of cell surface proteins, the team identified TACI as a previously unrecognized receptor for FGL1.

How Does FGL1 Actually Control B Cell Activation?

What makes this mechanism elegant is how FGL1 works without directly competing with the molecules that activate B cells. TACI normally receives activation signals from two cytokines called BAFF and APRIL. FGL1 binds to a different region of TACI, an N-terminal binding site, allowing it to regulate receptor function through a distinct mechanism.

When FGL1 attaches to TACI, it promotes the receptor's internalization, pulling it inside the cell and reducing the amount available on the B cell surface. By limiting receptor availability, FGL1 selectively suppresses activation of a subset of innate-like B cells without broadly shutting down all B cell responses. The protective effects were completely lost in mice lacking TACI, confirming that this receptor is essential for FGL1's immunosuppressive activity.

Ways This Discovery Could Transform Autoimmune Treatment

• Selective Suppression: Unlike current therapies that broadly suppress immunity or deplete B cells entirely, targeting the FGL1-TACI pathway allows doctors to dampen only the problematic immune responses while preserving protective immunity against infections.
• Reduced Infection Risk: By avoiding wholesale immune cell elimination, patients treated with FGL1-based therapies may maintain better protection against bacterial and viral infections compared to those on broad immunosuppressive drugs.
• Broader Disease Applications: While the research focused on lupus, excessive B cell activation and autoantibody production are hallmarks of many autoimmune diseases, suggesting this pathway could be relevant for conditions beyond lupus.

What Does This Mean for Lupus Patients?

Systemic lupus erythematosus (SLE), commonly called lupus, is a chronic autoimmune disease where the immune system attacks the body's own tissues. Excessive B cell activation and autoantibody production are central to lupus pathology. Current treatments often come with significant side effects because they suppress immunity broadly.

The discovery of the FGL1-TACI pathway establishes FGL1 as a previously unrecognized inhibitory ligand for B cells and identifies TACI as a novel immune checkpoint regulating humoral immunity, which is the antibody-producing arm of the immune system. This finding was published in the journal Immunity and represents a fundamental advance in understanding how the body naturally controls autoimmune responses.

Researchers emphasized that further work will determine whether therapies targeting this pathway can be translated into new treatments for lupus and other autoimmune disorders characterized by excessive B cell activity. The next steps involve moving from mouse models to human clinical trials, a process that typically takes several years. However, the specificity of this mechanism and its success in animal models suggest genuine promise for patients who currently have limited options beyond broad immunosuppression.